Virus Prevention Claims For RhinoSystems’ Naväge Flushed In Nasal Irrigation Advertising Review
Executive Summary
During NAD review, RhinoSystems stated it previously pulled some COVID-19 prevention claims NeilMed challenged and pulled remaining ads after review began. Both RhinoSystems, which markets Naväge brand, and NeilMed, offering a namesake brand, were warned in 2021 by FTC about COVID-19 ad claims.
You may also be interested in...
US FTC Diagnoses Omicron Symptom: More Fraudulent COVID-19 Treatment Claims
Agency says emergence of Omicron variant spurred marketers of products and services from peptide therapy to herbal remedies, and from nasal irrigation to intravenous drips to make false COVID-19 claims.
Navigating Amazon: E-Commerce Giant Critical For OTC Drug Sales
As Amazon emerges as the leading search engine for information about consumer packaged goods products, OTC drug and other consumer health product firms should establish a presence, even if they expect not to sell much, says BeeKeeper consultancy's Lynn Graham.
MacuHealth Asserts ‘Rigorous Process’ In Research Supporting Claims, But No Bill Of Health From NAD
“MacuHealth believes challenged claims are thoroughly supported by the multitude of peer reviewed, published scientific studies” but NAD review on Vision Elements challenge finds firm’s research doesn’t support its claims.